Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo

Journal of Cardiovascular Translational Research

Volumn 6, Issue 6, 2013, Pages 981-988

  Zanin, Valentina ^a   Marcuzzi, Annalisa ^a   Kleiner, Giulio ^a   Piscianz, Elisa ^a   Monasta, Lorenzo ^a   Zacchigna, Serena ^c   Crovella, Sergio ^a,b   Zauli, Giorgio ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Cholesterol; Cytokines; Inflammation; Statin

Indexed keywords

AMYLOID A PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEVINOLIN; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

MURINAE; MUS;

ANIMALS; CELL LINE; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; SERUM AMYLOID A PROTEIN; TIME FACTORS;

EID: 84890561448     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9506-8     Document Type: Article

References (31)

1. Goldstein, J. L.; Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343(6257), 425-430. doi: 10.1038/343425a0.
2. Biasucci, L. M.; Biasillo, G.; Stefanelli, A. (2010). Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC, 48(12), 1685-1691. doi: 10.1515/CCLM.2010.277.
3. Ray, K. K.; Cannon, C. P. (2005). The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. Journal of the American College of Cardiology, 46(8), 1425-1433. doi: 10.1016/j.jacc.2005.05.086.
4. Endres, M. (2006). Statins: potential new indications in inflammatory conditions. Atherosclerosis Supplements, 7(1), 31-35. doi: 10.1016/j. atherosclerosissup.2006.01.005.
5. Paoletti, R.; Corsini, A.; Bellosta, S. (2002). Pharmacological interactions of statins. Atherosclerosis Supplements, 3(1), 35-40.
6. Cordle, A.; Koenigsknecht-Talboo, J.; Wilkinson, B.; Limpert, A.; Landreth, G. (2005). Mechanisms of statin-mediated inhibition of small G-protein function. The Journal of Biological Chemistry, 280(40), 34202-34209. doi: 10.1074/jbc.M505268200.
7. Ehrenstein, M. R.; Jury, E. C.; Mauri, C. (2005). Statins for atherosclerosis - as good as it gets? The New England Journal of Medicine, 352(1), 73-75. doi: 10.1056/NEJMe048326.
8. Kuijk, L. M.; Mandey, S. H.; Schellens, I.; et al. (2008). Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Molecular Immunology, 45(8), 2158-2165. doi: 10.1016/j.molimm. 2007.12.008.
9. Coward, W. R.; Marei, A.; Yang, A.; Vasa-Nicotera, M. M.; Chow, S. C. (2006). Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. Journal of Immunology, 176(9), 5284-5292.
10. Monick, M. M.; Powers, L. S.; Butler, N. S.; Hunninghake, G. W. (2003). Inhibition of Rho family GTPases results in increased TNF-alpha production after lipopolysaccharide exposure. Journal of Immunology, 171(5), 2625-2630.
11. Bellosta, S.; Corsini, A. (2012). Statin drug interactions and related adverse reactions. Expert Opinion on Drug Safety, 11(6), 933-946. doi: 10.1517/14740338.2012.712959.
12. Marcuzzi, A.; De Leo, L.; Decorti, G.; Crovella, S.; Tommasini, A.; Pontillo, A. (2011). The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency. Pediatric Research, 70(1), 78-82. doi: 10.1038/pr.2011.30310.1203/ PDR.0b013e31821b581c.
13. Marcuzzi, A.; Tommasini, A.; Crovella, S.; Pontillo, A. (2010). Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes. International Immunopharmacology, 10(6), 639-642. doi: 10.1016/j.intimp.2010.03.008.
14. Deng, X.; Yu, Z.; Funayama, H.; et al. (2006). Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicology and Applied Pharmacology, 213(1), 64-73. doi: 10.1016/j.taap.2005.09.005.
15. Marcuzzi, A.; Secchiero, P.; Crovella, S.; Zauli, G. (2012). TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine, 60(1), 43-46. doi: 10.1016/j.cyto.2012.06.001.
16. Marcuzzi, A.; Pontillo, A.; De Leo, L.; et al. (2008). Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatric Research, 64(2), 177-182. doi: 10.1203/PDR. 0b013e3181761870.
17. Ni, W.; Egashira, K.; Kataoka, C.; et al. (2001). Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circulation Research, 89(5), 415-421.
18. Muniyappa, R.; Xu, R.; Ram, J. L.; Sowers, J. R. (2000). Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. American Journal of PHYSIOLOGY HEART and Circulatory Physiology, 278(6), H1762-H1768.
19. Ikeda, U.; Shimada, K. (2001). Pleiotropic effects of statins on the vascular tissue. Current Drug Targets Cardiovascular & Haematological Disorders, 1(1), 51-58.
20. Mantuano, E.; Santi, S.; Filippi, C.; et al. (2007). Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 61(6), 360-365. doi: 10.1016/j.biopha.2007.03.002.
21. Collins, G. S.; Altman, D. G. (2012). Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart, 98(14), 1091-1097. doi: 10.1136/heartjnl-2012-302014.
22. Rodriguez, A. L.; Wojcik, B. M.; Wrobleski, S. K.; Myers, D. D.; Jr.; Wakefield, T. W.; Diaz, J. A. (2012). Statins, inflammation and deep vein thrombosis: a systematic review. Journal of Thrombosis and Thrombolysis, 33(4), 371-382. doi: 10.1007/s11239-012-0687-9.
23. Watford, W. T.; Hissong, B. D.; Bream, J. H.; Kanno, Y.; Muul, L.; O'Shea, J. J. (2004). Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunological Reviews, 202, 139-156. doi: 10.1111/j.0105-2896. 2004.00211.x.
24. Jacobson, N. G.; Szabo, S. J.; Weber-Nordt, R. M.; et al. (1995). Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. The Journal of Experimental Medicine, 181(5), 1755-1762.
25. Satoh, S.; Oyama, J.; Suematsu, N.; et al. (2006). Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. International Journal of Cardiology, 111(3), 405-412. doi: 10.1016/j.ijcard.2005.08.021.
26. Matsumoto, M.; Einhaus, D.; Gold, E. S.; Aderem, A. (2004). Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. Journal of Immunology, 172(12), 7377-7384.
27. Taylor, J. J. (2010). Cytokine regulation of immune responses to Porphyromonas gingivalis. Periodontology 2000, 54(1), 160-194. doi: 10.1111/j.1600-0757.2009.00344.x.
28. Massonnet, B.; Normand, S.; Moschitz, R.; et al. (2009). Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. European cytokine network, 20(3), 112-120. doi: 10.1684/ecn.2009.0162.
29. Marcuzzi, A.; Piscianz, E.; Girardelli, M.; Crovella, S.; Pontillo, A. (2011). Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes. Apoptosis: an International Journal on Programmed Cell Death, 16(9), 882-888. doi: 10.1007/s10495-011-0621-1.
30. Almog, Y.; Shefer, A.; Novack, V.; et al. (2004). Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 110(7), 880-885. doi: 10.1161/01.CIR.0000138932.17956.F1.
31. Mekontso Dessap, A.; Ouanes, I.; Rana, N.; et al. (2011). Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study. Critical Care, 15(4), R171. doi: 10.1186/cc10317.